Skip to main content
logo
TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.3545
+0.0235 (7.10%)
Sep 17, 2026, 12:26 PM EDT - Market open

TScan Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
7.1110.332.8221.0513.5410.14
Revenue Growth
2.15%266.65%-86.62%55.52%33.47%834.65%
Cost of Revenue
95.43112.55107.3588.1559.8244.95
Gross Profit
-88.32-102.23-104.53-67.1-46.28-34.81
Selling, General & Admin
30.2231.5930.2926.3520.3513.83
Operating Expenses
30.2231.5930.2926.3520.3513.83
Operating Income
-118.54-133.81-134.82-93.46-66.64-48.64
Interest Expense
-2.79-2.77-3.65-3.76-1.18-
Interest & Investment Income
5.628.8212.0781.590.02
EBT Excluding Unusual Items
-115.71-127.77-126.41-89.22-66.22-48.63
Merger & Restructuring Charges
-2-2----
Other Unusual Items
---1.09---
Pretax Income
-117.71-129.77-127.5-89.22-66.22-48.63
Net Income
-117.71-129.77-127.5-89.22-66.22-48.63
Net Income to Common
-117.71-129.77-127.5-89.22-66.22-48.63
Net Income Growth
------
Shares Outstanding (Basic)
685757482412
Shares Outstanding (Diluted)
685757482412
Shares Change
19.44%0.55%18.32%98.89%106.20%1173.20%
EPS (Basic)
-1.74-2.28-2.25-1.87-2.75-4.17
EPS (Diluted)
-1.74-2.28-2.25-1.87-2.75-4.17
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-118.44-139.73-114.65-64.5-70.73-58.62
Free Cash Flow Per Share
-1.75-2.46-2.03-1.35-2.94-5.03
Operating Margin
-1667.02%-1296.01%-4787.68%-444.00%-492.32%-479.65%
Profit Margin
-1655.35%-1256.81%-4527.66%-423.86%-489.26%-479.49%
Free Cash Flow Margin
-1665.57%-1353.28%-4071.27%-306.45%-522.56%-578.03%
EBITDA
-115.66-130.95-130.71-88.1-61.5-45.31
D&A For EBITDA
2.882.874.115.365.143.33
EBIT
-118.54-133.81-134.82-93.46-66.64-48.64
SEC Filings: 10-K · 10-Q